For those dealing with fatty liver disease, there’s welcome news to report. Earlier this year, the United States Food and ...

Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...

Since then, sales have been exploding. Revenues from the MASH drug Rezdiffra grew by over 400% from Q2 of this year to Q3.

Rezdiffra (resmetirom) is a prescription drug used to treat certain types of nonalcoholic steatohepatitis (NASH). Rezdiffra can cause side effects that range from mild to serious, such as diarrhea ...

Here are three reasons why it's a canny move to buy the stock. When it was approved in March 2024, Rezdiffra became the only medicine approved by the Food and Drug Administration (FDA) to treat ...

Rezdiffra (resmetirom) is a brand-name oral tablet prescribed for nonalcoholic steatohepatitis (NASH) in certain situations. It is typically taken once per day. The dosage varies based on a person ...

As the first oral treatment for this condition, Rezdiffra's launch and market performance are crucial factors in determining the company's future success and stock performance. According to ...

While the medication resmetirom (Rezdiffra) helps to treat this condition, you need to use it along with lifestyle changes for weight loss. So what should you eat? In general, the more plant ...

The catalyst? A stellar third-quarter report for Rezdiffra, Madrigal's flagship treatment for NASH (a severe liver condition). The numbers don't lie: $62.2 million in sales, crushing Wall Street's ...

Rezdiffra (resmetirom) is a brand-name oral tablet that’s prescribed for a form of liver disease called nonalcoholic steatohepatitis (NASH). As with other drugs, Rezdiffra can cause side effects ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of $6.66 billion, has positioned itself as a frontrunner in the treatment of nonalcoholic steatohepatitis (NASH) with its ...